论文信息 - Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours - 字舞流文

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Mikkel A. Algire | L. Lam | Chaohong Sun | K. Bromberg | Chunaram Choudhary | M. Michaelides | P. Cole | R. Marmorstein | B. Weinert | S. Rosenberg | C. Jakob | T. Uziel | Emily J. Faivre | E. DiGiammarino | M. Patane | R. Edalji | G. Chiang | R. Frey | Ruth L. Martin | M. Torrent | J. V. Van Drie | T. M. Hansen | A. Kluge | Loren M. Lasko | W. Qiu | V. Manaves | E. Kesicki | Kannan R. Karukurichi | F. G. Buchanan | D. Montgomery | A. Lai | D. Ferguson | P. Hessler | J. Langston | B. Shaw | R. Risi | Ce Wang | D. McElligott | Peter de Vries

[1] Mikkel A. Algire,et al. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. , 2017, Nature chemical biology.

[2] Mariko Sasaki,et al. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. , 2016, Cancer discovery.

[3] Julie M. Garlick,et al. Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300. , 2016, ACS medicinal chemistry letters.

[4] W. Sippl,et al. KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases. , 2016, Journal of medicinal chemistry.

[5] Tony Kouzarides,et al. Histone core modifications regulating nucleosome structure and dynamics , 2014, Nature Reviews Molecular Cell Biology.

[6] P. Cole,et al. Structure of the p300 Histone Acetyltransferase Bound to Acetyl-Coenzyme A and Its Analogues , 2014, Biochemistry.

[7] D. Tindall,et al. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. , 2014, Cancer research.

[8] R. Young,et al. Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[9] P. Kaufman,et al. A small molecule inhibitor of fungal histone acetyltransferase Rtt109. , 2013, Bioorganic & medicinal chemistry letters.

[10] A. Melnick,et al. The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation , 2011, Science.

[11] W. Parson,et al. Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines , 2011, Molecular Cancer Therapeutics.

[12] Li-Rong Yu,et al. Distinct roles of GCN5/PCAF‐mediated H3K9ac and CBP/p300‐mediated H3K18/27ac in nuclear receptor transactivation , 2011, The EMBO journal.

[13] S. Srivastava,et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence , 2010, Prostate Cancer and Prostatic Diseases.

[14] Ruben Abagyan,et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[15] Ling Wang,et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator , 2008, Nature.

[16] T. Kundu,et al. Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression* , 2004, Journal of Biological Chemistry.

[17] R. Roeder,et al. Regulation of the p300 HAT domain via a novel activation loop , 2004, Nature Structural &Molecular Biology.

[18] T. Tammela,et al. Expression of Androgen Receptor Coregulators in Prostate Cancer , 2004, Clinical Cancer Research.

[19] D. Tindall,et al. p300 in prostate cancer proliferation and progression. , 2003, Cancer research.

[20] R. Marmorstein. Structure of histone acetyltransferases. , 2001, Journal of molecular biology.

[21] V. Ogryzko,et al. p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation* , 2000, The Journal of Biological Chemistry.

[22] R. Roeder,et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. , 2000, Molecular cell.